Testosterone replacement therapy taken for up to 5 years is not associated with an increase in the risk that older men will develop high-grade prostate cancer, according to a study with more than 50,000 men with prostate cancer.
The results were published in the December issue of the Journal of Urology.
This study extends the length of time testosterone therapy, commonly known as T, has been studied in men who are subsequently diagnosed high-grade disease, explain the authors, led by Jacques Baillargeon, MD, from the University of Texas Medical Branch in Galveston.
"To date only one population-based study has been done to examine whether exposure to testosterone therapy increases the risk of high-grade prostate cancer," they write, referring to an analysis that examined up to 1 year of testosterone therapy use before a diagnosis of prostate cancer (Urology. 2013;82:321-326).